{"schema_version":"secwatch.filing_event.v1","accession":"0001773751-25-000152","form_type":"8-K","ticker":"HIMS","cik":"0001773751","company_name":"Hims & Hers Health, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.662657+00:00","generated_at":"2026-05-22T17:57:21.937850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Hims & Hers Q1 revenue $586M (+111% YoY), net income $49.5M, raises EBITDA guidance","bullets":["Revenue $586M (+111% YoY); net income $49.5M (up 345% YoY); Adj. EBITDA $91.1M (up 182% YoY).","Subscribers 2.4M (+38% YoY); monthly online rev per sub $84 (+53% YoY).","Affirms FY2025 revenue guidance $2.3-$2.4B; raises Adj. EBITDA outlook to $295-$335M.","Introduced 2030 targets of at least $6.5B revenue and $1.3B Adj. EBITDA.","Gross margin 73% (down 900bps YoY) on GLP-1 mix; partnered with Novo Nordisk for Wegovy access."],"urls":{"canonical":"https://secwatch.observer/filing/0001773751-25-000152","json":"https://secwatch.observer/filing/0001773751-25-000152.json","markdown":"https://secwatch.observer/filing/0001773751-25-000152.md","text":"https://secwatch.observer/filing/0001773751-25-000152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1773751/000177375125000152/0001773751-25-000152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1773751/000177375125000152/hims-20250505.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T17:57:21.937850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}